Extracellular vesicles in kidney disease

Cristina Grange1 and Benedetta Bussolati2✉

Abstract | Extracellular vesicles are released by the majority of cell types and circulate in body fluids. They function as a long-distance cell-to-cell communication mechanism that modulates the gene expression profile and fate of target cells. Increasing evidence has established a central role of extracellular vesicles in kidney physiology and pathology. Urinary extracellular vesicles mediate crosstalk between glomerular and tubular cells and between different segments of the tubule, whereas circulating extracellular vesicles mediate organ crosstalk and are involved in the amplification of kidney damage and inflammation. The molecular profile of extracellular vesicles reflects the type and pathophysiological status of the originating cell so could potentially be exploited for diagnostic and prognostic purposes. In addition, robust preclinical data suggest that administration of exogenous extracellular vesicles could promote kidney regeneration and reduce inflammation and fibrosis in acute and chronic kidney diseases. Stem cells are thought to be the most promising source of extracellular vesicles with regenerative activity. Extracellular vesicles are also attractive candidates for drug delivery and various engineering strategies are being investigated to alter their cargo and increase their efficacy. However, rigorous standardization and scalable production strategies will be necessary to enable the clinical application of extracellular vesicles as potential therapeutics.

Extracellular vesicles are a heterogeneous population of membrane-bound vesicles that are considered to be central messengers for intercellular communication1. They are released by the majority of cell types and can be classified into two main categories depending on their origin: exosomes, which are released by the endosomal compartment and have an average size of 100 nm, and ectosomes, which are released by budding of the plasma membrane and range in size from microvesicles to large vesicles (50 nm to 1 μm)2,3. Apoptotic bodies that are released by cells undergoing apoptosis4, large tumour-derived vesicles (oncosomes)5 and mitochondrial-derived vesicles (mitovesicles)6, are also classed as extracellular vesicles.

Exosomes originate from a sequential process that begins with invagination of the plasma membrane and the de novo formation of early-sorting endosomes that contain a mixture of cell-surface proteins and extracellular components. The early-sorting endosomes mature into late-sorting endosomes and the trans-Golgi network and the endoplasmic reticulum participate in sorting and defining the content of the endosomes7. The late sorting endosomes give rise to multivesicular bodies, the future exosomes (Fig. 1). Multivesicular bodies can fuse with lysosomes to be degraded or with the cellular membrane to shed mature exosomes2.

The biogenesis of exosomes is regulated by the endosomal sorting complexes required for transport (ESCRT) pathway. Some ESCRT proteins, including tumour susceptibility gene 101 protein (TSG101), ALG2-interacting protein X (ALIX), soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) and heat shock protein 90 (HSP90), are present in the released exosomes8. The tetraspanins CD9, CD63 and CD81 are commonly used as biomarkers for exosome identification4. However, given the uncertain boundary between exosomes and ectosomes in terms of size and markers, some studies simply subdivide extracellular vesicles into small (<100 nm), medium (100–200 nm) and large extracellular vesicles (>200 nm)4.

Despite the heterogeneous and diverse nature of extracellular vesicles, their central role in numerous physiological and pathological conditions has been clearly defined. Extracellular vesicles are present at high levels in biological fluids and can be easily isolated from these fluids. Their complex cargo reflects the type and pathophysiological status of the originating cell and so represents an important source of information. Extracellular vesicles can be internalized by target cells in an archaic form of long-distance cell-to-cell communication that has been retained throughout evolution7. Differences in their size and surface molecules may affect their ability to be internalized. Several mechanisms of extracellular vesicle internalization have been observed, including endocytosis, micro-pinocytosis, phagocytosis, plasma or endosomal fusion.
Key points

- Urinary extracellular vesicles have roles in intra-glomerular, glomerulo-tubular and intra-tubular crosstalk, whereas circulating extracellular vesicles might mediate organ crosstalk; these mechanisms could amplify kidney damage and contribute to disease progression.
- Urinary extracellular vesicles could potentially be analysed using multiplex diagnostic platforms to identify pathological processes and the originating cell types; technological advances including single extracellular vesicle analysis might increase the specificity of bulk analysis of extracellular vesicle preparations.
- Robust standardization and validation in large patient cohorts are required to enable clinical application of extracellular vesicle-based biomarkers.
- Stem cell-derived extracellular vesicles have been shown to improve renal recovery, limit progression of injury and reduce fibrosis in animal models of acute kidney injury and chronic kidney disease.
- Various engineering approaches can be used to load extracellular vesicles with therapeutic molecules and increase their delivery to the kidney.
- A small clinical trial that tested the efficacy of mesenchymal stem cell extracellular vesicle administration in patients with chronic kidney disease reported promising results; however, therapeutic application of extracellular vesicles is limited by a lack of scalable manufacturing protocols and clear criteria for standardization.

Transcytosis
A type of transcellular transport in which macromolecules are captured in vesicles on one side of the cell and then transported across and released on the other side of the cell.

Urinary extracellular vesicles are a heterogeneous population that mainly originate from the cells of the urogenital tract; the most prevalent sources of these vesicles are glomerular, tubular, prostate and bladder cells. A proteomic analysis demonstrated that 99.96% of the proteins present in urinary extracellular vesicles are characteristic of cells of the urogenital tract. Urinary extracellular vesicles express typical apical membrane markers, such as transporters and channels, but do not express exclusively basolateral markers, suggesting that they mainly originate from the apical membranes of urogenital cells. A comparison of kidney-derived urinary extracellular vesicles (obtained from patients with nephrostomy drains) with extracellular vesicles derived from the complete urinary tract showed that the vast majority of urinary extracellular vesicle proteins are present in both types of samples, suggesting that the kidney is the main source of urinary extracellular vesicles.

A small fraction of urinary extracellular vesicle proteins (0.04%) are not characteristic of urogenital cells, raising the possibility that some of these vesicles originate from kidney-infiltrating cells or from serum-circulating extracellular vesicles. However, the latter possibility seems unlikely in the presence of an intact glomerular filtration barrier as the slit diaphragm may only allow passage of 4-nm structures. Serum extracellular vesicles could potentially cross the podocyte layer via a process of transcytosis. A study that used a microfluidic model to reproduce the glomerular barrier demonstrated that serum extracellular vesicles that were engineered to express cel-miR-39 from Caenorhabditis elegans were able to pass through this barrier and transfer the exogenous microRNA (miRNA) to human podocytes. Urinary excretion of intravenously injected labelled extracellular vesicles has been shown in rats but, to date, urinary excretion of endogenous non-urinary extracellular vesicles has not been clearly demonstrated.

Passage of extracellular vesicles through the filtration barrier can be expected in pathological conditions in which basal membrane rupture allows the passage of large structures such as erythrocytes. For example, in rodent models, AKI increased the renal biodistribution of intravenously injected labelled extracellular vesicles. These extracellular vesicles were rapidly (5 min after injection) taken up by proximal tubule cells.

Role in intra-nephron communication
Several studies have suggested a potential role of urinary extracellular vesicles in intra-nephron communication across the glomerular and tubular regions. Extracellular vesicles released by cells in the upper segments of tubules can be internalized by downstream cells, transferring active molecules and modulating the behaviour of the recipient cells. One of the first studies of intra-tubular extracellular vesicle communication reported that cultured murine kidney collecting duct cells could transfer functional aquaporin 2 (AQP2) via the release and uptake of extracellular vesicles. A subsequent study showed that labelled extracellular vesicles isolated from proximal tubular cells could be taken up in vitro by distal tubule and collecting duct cells. A study published in preprint form provided evidence of the physiological transfer of extracellular RNAs, likely carried by extracellular vesicles, along the nephron in mice. In this study, podocyte RNA was labelled using a sequence-based metabolic approach (SH-linked alkylation for the metabolic sequencing of RNA) and subsequently detected in tubular cells, suggesting transfer from the glomerulus to the tubular region.
Role in amplification of kidney disease

Extracellular vesicle-mediated long-distance cell-to-cell communication between different regions of the kidney and between different organs could amplify kidney damage. In vitro studies suggest that altered extracellular vesicle-mediated communication between glomerular endothelial cells and podocytes might impair podocyte functions. Moreover, podocyte extracellular vesicles might mediate crosstalk between the glomeruli and the tubules and thereby promote tubular injury. This mechanism could contribute to the amplification of damage, the development of tubulointerstitial fibrosis and the progression of CKD.

Cultured human podocytes that were exposed to damaging stimuli (cyclical stretch or high glucose) released an elevated number of extracellular vesicles compared with untreated podocytes. These extracellular vesicles were taken up by proximal tubule epithelial cells in vitro and induced a profibrotic phenotype with expression of fibronectin and collagen IV and activation of p38 and mothers against decapentaplegic homologue 3 (SMAD3). This mechanism could contribute to the amplification of damage, the development of tubulointerstitial fibrosis and the progression of CKD.

Extracellular vesicles might also have a role in tubulointerstitial inflammation, which promotes kidney disease progression. In various murine models, high tubular expression of hypoxia-inducible factor 1α (HIF1α) in combination with an inflammatory milieu promoted the release of miR-23a-enriched extracellular vesicles by tubular epithelial cells. When taken up by macrophages, these extracellular vesicles induced reprogramming of the cells into a pro-inflammatory state, amplifying the inflammatory cascade. These studies clearly indicate a role of extracellular vesicles released by injured cells along the nephron in the progression of kidney injury (Fig. 2). Whether extracellular vesicles might also be released by regenerating renal cells and support a positive paracrine effect is unknown.

Extracellular vesicles that are released into the circulation by distant tissues might have a role in intra-organ crosstalk and in the amplification of pathological conditions characterized by multi-organ dysfunction. Such crosstalk was suggested by a proteomic analysis of extracellular vesicles isolated from the murine heart that identified proteins that seemed to originate from various other organs, including the kidney. Extracellular vesicles from other organs might also affect the kidney. For example, in pre-eclampsia, placenta-derived extracellular vesicles carrying anti-angiogenic factors that are released into the maternal circulation might lead to glomerular endothelial dysfunction and proteinuria. Circulating extracellular vesicles in autoimmune diseases, such as systemic lupus erythematosus, antiphospholipid syndrome and ANCA-associated
vasculitis, might promote coagulation, thrombosis and immune-mediated renal pathological conditions. CKD-related cardiovascular dysfunction has been associated with high levels of circulating endothelial-derived microparticles that may mediate vascular remodelling, vascular wall injury and inflammation. These microparticles are also associated with increased risk of vascular calcification in CKD, as well as with kidney failure and anaemia. Extracellular vesicles might also contribute to the worsening of kidney damage during liver or heart disease and vice versa, thereby participating in the development of hepatorenal or cardiorenal syndrome. However, further research is needed to investigate this possibility. The development of single extracellular vesicle analysis and in vivo tracking approaches will help to elucidate the roles of extracellular vesicles in inter-organ and intra-organ communication.

**Extracellular vesicle biomarkers**

Urinary extracellular vesicles are promising candidates for the identification of non-invasive biomarkers to predict and monitor the progression of pathological conditions of the kidney (Table 1). An advantage of urinary extracellular vesicle biomarkers is that they could potentially be analysed using a multiplex diagnostic platform to identify pathological processes and the originating cell types. Changes in the extracellular vesicle
cargo might occur before alterations of classical serum markers of kidney function, such as urea and creatinine levels, enabling early diagnosis. However, several factors currently limit the clinical application of urinary extracellular vesicle biomarkers.

Standardized methods for urine collection and preservation and protocols for extracellular vesicle isolation and removal of contaminants are critical to guarantee reproducibility of results and limit artefacts. Moreover, the lack of a standardized methodology for urinary extracellular vesicle quantification and, more importantly, normalization, might affect results and reproducibility between different centres. Urinary creatinine concentration has been proposed as a normalizer for urinary extracellular vesicle concentration because it correlates with particle number and its excretion is not affected by water intake. In addition, tetraspanin levels could be used as normalizers for urinary extracellular vesicle quantity. Nephron mass directly correlates with urinary extracellular vesicle excretion and so should also be considered when comparing biomarker levels.

Biomarkers of kidney injury and disease

Studies in rodent models of AKI identified decreased levels of aquaporin 1 (AQP1) and increased levels of fetuin A and activating transcription factor 3 (ATF3) in urinary extracellular vesicles as potential biomarkers of tubular damage. However, these data have only been validated in a small number of patients. A slightly more robust body of literature supports the detection of urinary extracellular vesicle markers as an early sign of podocyte injury. For example, the number of podoplanin-expressing large extracellular vesicles in urine was reported to be a marker of diabetic glomerular injury in a mouse model. The urinary extracellular vesicle expression of Wilms tumour protein (WT1) is another potential biomarker of podocyte injury. The level of urinary exosomal WT1 was significantly higher in 7 patients with focal segmental glomerulosclerosis than in 5 healthy volunteers. Similarly, in a cohort of 48 patients with type 1 diabetes mellitus (T1DM), increased urinary extracellular vesicle levels of WT1 were correlated with proteinuria and a decline in estimated glomerular filtration rate. By contrast, a study that included 40 children with idiopathic nephrotic syndrome, reported no significant differences in exosomal WT1 expression between those with different levels of proteinuria, renal pathological conditions or steroid responsiveness. A study that included 32 patients with kidney disease reported that reduced levels of the podocyte-specific CD2AP mRNA in urinary extracellular vesicles were associated with kidney fibrosis and correlated with serum creatinine levels and glomerular filtration rate.

Another potential application of urinary extracellular vesicles is in the monitoring of kidney graft function. The levels of urinary extracellular vesicles expressing the

| Disease                        | Marker          | Level compared with healthy individuals | Type of damage or regeneration | Detection method | Refs |
|-------------------------------|-----------------|------------------------------------------|--------------------------------|------------------|------|
| Acute kidney injury           | AQP1            | Decreased*                               | Tubular cell injury           | Western blot     | 44   |
|                               | ATF3 mRNA       | Increased*                               |                                 | qRT-PCR          | 46   |
|                               | Fetuin A        | Increased*                               |                                 | MALDI-TOF, LC–MS/MS, western blot | 45   |
| Focal segmental glomerulosclerosis | WT1            | Increased*                               | Podocyte damage               | Western blot     | 47   |
| Type 1 diabetes mellitus      | WT1             | Increased                                | Podocyte damage               | Western blot     | 48   |
|                               | miR-130a and miR-145 | Increased*                              | Glomerular mesangial damage   | qRT-PCR          | 56   |
|                               | miR-155 and miR-424 | Decreased*                             |                                 | qRT-PCR          |      |
| Chronic kidney disease        | CD2AP mRNA      | Decreased                                | Podocyte damage               | qRT-PCR          | 50   |
|                               | miR-29          | Decreased                                | Fibrosis                      | qRT-PCR          | 57   |
|                               | miR-200b        | Increased                                |                                 | qRT-PCR          | 58   |
|                               | miR-181a-5p and miR-451 | Increased                  | Not known                     | qRT-PCR          | 59  |
| IgA nephropathy               | miR-215-5p and miR-378i | Increased                  | Not known                     | qRT-PCR          | 60   |
| Lupus nephritis               | miR-146a, miR-150 and miR-21 | Increased                  | Fibrosis                      | qRT-PCR          | 61   |
| Kidney transplantation        | NGAL            | Increased                                | Tubular cell injury           | Western blot     | 51   |
|                               | CD133           | Decreased                                | Tubular cell regeneration     | FACS, western blot | 52   |

AQP1, aquaporin 1; FACS, fluorescence-activated cell sorting; LC, liquid chromatography; MALDI-TOF, matrix-assisted laser desorption/ionization time of flight; MS, mass spectrometry; NGAL, neutrophil gelatinase-associated lipocalin; qRT-PCR, quantitative real-time polymerase chain reaction; WT1, Wilms tumour protein 1. *Also demonstrated in rodent models.
kidney injury marker neutrophil gelatinase-associated lipocalin (NGAL) were increased and the levels of those expressing the renal progenitor cell marker CD133 were decreased in transplant recipients with delayed graft function, reflecting tubular cell injury and regeneration, respectively.2,3,5

Modulation of miRNAs may also characterize renal diseases or their evolution. The presence of RNA species in extracellular vesicle cargos was first reported in 2007 (Ref. 5). Exosomal miRNAs are more stable than free miRNAs as they are protected from degradation owing to RNase activity in biofluids6. Numerous miRNAs within urinary extracellular vesicles are dysregulated during CKD, kidney fibrosis and diabetic kidney disease (DKD)7. A study of urinary extracellular vesicles from patients with T1DM showed enrichment of miR-130a and miR-145 and a reduction of miR-155 and miR-424 in those from patients with microalbuminuria.16

miR-29c seems to be one of the most consistently altered miRNAs in kidney disease. A study that included 32 patients with CKD reported that the levels of miR-29c were decreased and that levels of miR-200b were increased in urinary extracellular vesicles from these patients compared with healthy individuals.17 Moreover, the level of miR-29c in urinary extracellular vesicles correlated with estimated glomerular filtration rate and the severity of tubulointerstitial fibrosis. Other miRNAs that are overexpressed in urinary extracellular vesicles from patients with CKD include miR-181a-5p and miR-451 (Ref. 18). In urinary extracellular vesicles from 18 patients with IgA nephropathy, miR-29c and miR-205-5p were downregulated, whereas miR-215-5p and miR-378i were upregulated compared with those from healthy individuals.19 Decreased levels of miR-29c and increased levels of miR-150 and miR-21 in urinary extracellular vesicles from patients with lupus nephritis were associated with kidney fibrosis. These miRNAs promote fibrosis by acting on the TGFβ–SMAD3 pathway and regulating collagen production.20 Other classes of molecules in extracellular vesicles, such as small RNA species, should also be investigated as candidate biomarkers. For example, circular RNAs were reported to be upregulated in blood and urinary extracellular vesicles from patients with membranous nephropathy.21

Although a number of promising candidate biomarkers for kidney diseases have been identified, the heterogeneity of urinary extracellular vesicle analyses and the small number of patients included in published studies preclude their readiness for clinical translation. Robust standardization, studies with large numbers of patients and reproduction of findings in independent cohorts is needed to enable clinical translation. In addition, technological advances, including single extracellular vesicle analysis using flow cytometry or arrays based on extracellular vesicle-capturing chips22, might increase the specificity of results in comparison with bulk analyses of urinary extracellular vesicle preparations.

Biomarkers of renal cell carcinoma
Cancer-derived extracellular vesicles influence the tumour microenvironment and sustain and promote cancer progression.23 As the levels of these extracellular vesicles increase in blood and urine as cancer develops, they are promising candidates for the identification of non-invasive diagnostic biomarkers. One of the first studies that compared the proteomic profiles of urinary extracellular vesicles from patients with renal cell carcinoma (RCC) and healthy individuals identified several specific markers of RCC, including increased expression of metalloproteinase 9 (MMP9), ceruloplasmin, podocalyxin, carbonic anhydrase 9 (CAIX) and dihydrofolate-related protein 4 (DHFR4), and decreased expression of nephrilysin (also known as CD10), extracellular matrix metalloproteinase inducer (EMMPRIN; also known as basigin), dipeptidase 1, syntenin 1 and AQP1 (Ref. 24). An ongoing clinical trial is aimed at using electron microscopy to detect urinary extracellular vesicles that express CAIX in combination with the exosomal marker CD9 in the urine of patients with clear-cell renal cell carcinoma (ccRCC).25

Urinary extracellular vesicle miRNAs have also been investigated as biomarkers of RCC. The presence of increased levels of miR-126-3p combined with miR-449a or miR-34b-5p in urinary extracellular vesicle cargo was reported to distinguish between patients with ccRCC and healthy individuals.26 Another study reported upregulation of miR-204-5p in urinary exosomes from patients with Xp11 translocation RCC (a rare sporadic paediatric kidney cancer), suggesting that this upregulation could be a useful biomarker for early diagnosis.27 Increased serum levels of miR-224 have been proposed as a biomarker of poor prognosis in patients with ccRCC, whereas upregulation of serum exosomal miR-210 might distinguish patients with ccRCC from healthy individuals.28 Altered miRNA expression in plasma extracellular vesicles from patients with RCC has also been described, with upregulation of miR-149-3p and miR-424-3p and downregulation of miR-92a-1-5p.29

The RNA profile and long non-coding RNAs (lncRNAs) have also been proposed as new classes of urinary extracellular vesicle RCC biomarkers. LncRNAs can be selectively compartmentalized into extracellular vesicles and can modulate cancer progression and drug resistance.30 For example, sunitinib-resistant RCC cells express a high level of IncARSR compared with sunitinib-sensitive RCC cells31. This lncRNA can be transferred via extracellular vesicles to recipient cells, potentially transmitting drug resistance.32

Therapeutic use of extracellular vesicles
Evidence from preclinical models of AKI, CKD and kidney transplant preconditioning suggests that extracellular vesicles from various sources, particularly those released by stem cells, have therapeutic properties and can accelerate kidney recovery.33 (Fig. 3). Mesenchymal stromal cells (MSCs) are currently the most utilized cell source for regenerative medicine owing to their well-established immunomodulatory, pro-regenerative and anti-inflammatory properties.34 MSC extracellular vesicles are active components of the MSC secretome that are responsible for many of these beneficial effects.35,36 However, extracellular vesicles from other sources, including kidney cells, might also have therapeutic activity.
Stem cell-derived extracellular vesicles

Several key characteristics could potentially make stem cell-derived extracellular vesicles more effective therapeutic agents than the cells from which they are secreted. Extracellular vesicles may be less immunogenic, less toxic and more able to cross biological barriers than stem cells. Moreover, extracellular vesicles are intrinsically stable in the circulation owing to their negatively charged surface and they may have targeting properties that are dictated by their lipid composition and surface molecules. Further studies are required to assess whether delivery of extracellular vesicles could confer more effective renoprotection than delivery of their parental MSCs.

Acute kidney injury. The therapeutic effects of MSC extracellular vesicles have been well established since 2009, when a pioneering study demonstrated that intravenously injected bone marrow (BM)-MSC extracellular vesicles promoted tissue repair in a murine model of rhabdomyolysis-induced AKI (Supplementary Table 1). In models of toxic and ischaemic AKI, BM-MSC extracellular vesicles promoted tubular cell proliferation and limited apoptosis, resulting in amelioration of loss of kidney function and reductions in plasma urea nitrogen and creatinine levels. Similarly, administration of adipose MSC extracellular vesicles reduced inflammation and ameliorated kidney damage in models of cisplatin-induced and sepsis-induced AKI. The protective mechanism in septic AKI involved an increase in sirtuin 1 (SIRT1) and a reduction in NF-κB levels in renal tissues; whereas in cisplatin-induced AKI, the mechanism involved modulation of miRNAs (miR-880, miR-146b and inhibition of NF-κB88). Similar nephroprotective effects of extracellular vesicles derived from umbilical cord MSC extracellular vesicles have been reported in IRI models, umbilical cord MSC extracellular vesicles reduced inflammation and improved survival via upregulation of miR-146b and inhibition of NF-κB. Similar nephroprotective effects of extracellular vesicles derived from placenta, induced pluripotent stem cell (iPSC)-derived MSCs and iPSCs have been shown to alleviate inflammation by promoting the expansion of regulatory T (Treg) cells and M2 macrophages. Wharton jelly MSC extracellular vesicles also protected against oxidative stress and apoptosis via activation of the extracellular-regulated kinase (ERK) pathway in a cisplatin AKI model.

In rat ischaemia–reperfusion injury (IRI) models, umbilical cord MSC extracellular vesicles have been reported to promote tubular cell dedifferentiation and regeneration by stimulating the production of hepatocyte growth factor and to mitigate apoptosis and enhance proliferation of kidney cells as well as alleviate inflammation via suppression of CX3C-chemokine ligand 1 (CX3CL1, also known as fractalkine) expression.

Fig. 3 | Application of stem cell-derived extracellular vesicles for kidney regeneration. Data from studies in animal models suggest that the treatment with stem cell-derived extracellular vesicles can accelerate renal repair in acute kidney injury and chronic kidney disease, promote proximal tubular epithelial cell (PTEC) proliferation, improve renal oxygenation and inhibit PTEC dedifferentiation, inflammation, apoptosis and fibrosis. Various mechanisms have been reported to underlie these beneficial effects. For example, extracellular vesicle miRNAs have been shown to induce semaphorin 3A downregulation, resulting in a reduction in apoptosis, to target genes involved in fibrosis progression such as Col1a1, Acta2 and Sna1 and thereby inhibit fibrosis, and to downregulate Toll-like receptor 4 (TLR4) in podocytes, resulting in a reduction in inflammation and podocyte damage. Mesenchymal stromal cell extracellular vesicles have also been reported to attenuate inflammation by promoting the expansion of regulatory T (Treg) cells and M2 macrophages. αSMA, α-smooth muscle actin; SNAI1, zinc-finger protein SNAI1.

Wharton jelly. Mucous connective tissue of the umbilical cord located between the amniotic epithelium and the umbilical vessels.
inhibition of necroptosis\textsuperscript{40}. Extracellular vesicles derived from iPSCs promoted kidney regeneration by protecting mitochondrial function and reducing oxidative stress and inflammation\textsuperscript{98}. Studies using cisplatin-induced AKI and kidney IRI models have also reported that extracellular vesicles isolated from BM-MSCs and endothelial progenitor cells can limit AKI to CKD progression\textsuperscript{10,14,41}. BM-MSC extracellular vesicles stimulated the expression of anti-apoptotic genes, such as Bcl2l1, Bcl2 and Birc8, in damaged tubular cells\textsuperscript{41}, whereas endothelial progenitor cell-derived extracellular vesicles induced kidney regeneration via the transfer of angiogenic miRNAs such as miR-126 and miR-296 (REF.\textsuperscript{73}). These findings are important because even a single episode of AKI can increase the risk of developing CKD or accelerate the progression of existing CKD\textsuperscript{94}. Extracellular vesicles isolated from embryonic stem cells have also been shown to promote kidney repair following AKI\textsuperscript{94}. An advantage of these cells is that they can proliferate indefinitely in vitro, enabling continuous isolation of extracellular vesicles\textsuperscript{94}. Studies using extracellular vesicles derived from endothelial progenitor cells and adult endothelial colony-forming cells have also reported protective effects in various models of kidney injury\textsuperscript{52,60–62}. Currently, there is no evidence to suggest that extracellular vesicles from any particular stem cell source are superior to other stem cell-derived extracellular vesicles for amelioration of kidney damage.

### Chronic kidney disease

An increasing number of studies have investigated the therapeutic potential of stem cell-derived extracellular vesicles in models of CKD, using various doses and administration approaches (Supplementary Table 1). Similar to AKI studies, the most frequently utilized cell source for CKD studies is MSCs. However, unlike AKI studies, the majority of preclinical CKD studies use multiple rather than single injections of extracellular vesicles.

In a porcine model of renal artery stenosis, adipose-derived-MSC extracellular vesicles were shown to localize in tubular cells and macrophages within the stenotic kidney, attenuate renal inflammation and improve renal oxygenation and function via delivery of the anti-inflammatory cytokine IL-10 (REF.\textsuperscript{99}). A subsequent study in a porcine model of metabolic syndrome and renal artery stenosis reported that intrarenal injection of MSC extracellular vesicles promoted the expansion of regulatory T cells, upregulation of anti-inflammatory M2 macrophages and a reduction in pro-inflammatory M1 macrophages\textsuperscript{99}. These effects attenuate inflammation and consequently favour kidney regeneration.

Inhibiting the fibrotic process to limit or revert the progression of CKD is a major challenge in nephrology. Multiple injections of BM-MSC extracellular vesicles were shown to prevent kidney failure in a mouse five-sixth nephrectomy model, in rodent models of kidney fibrosis induced by unilateral ureteral obstruction (UUO) and in a mouse model of aristolochic acid-induced CKD\textsuperscript{100–104}. Administration of BM-MSC extracellular vesicles also resulted in reversion of renal fibrosis via the delivery of anti-fibrotic miRNAs in a mouse model of streptozotocin-induced diabetic nephropathy\textsuperscript{97}.

Robust data support beneficial effects of MSC extracellular vesicles in models of DCD via various mechanisms, potentially including the induction of autophagy in kidney cells\textsuperscript{16,107} and the transfer of miR-26a-5p\textsuperscript{108}. This miRNA was shown to target and inhibit Toll-like receptor 4 (TLR4), resulting in inactivation of the NF-kB pathway and limiting podocyte damage\textsuperscript{109}. In a rat UUO model, infusion of human umbilical cord MSC extracellular vesicles reduced kidney fibrosis through the delivery of casein kinase 1δ and E3 ubiquitin ligase β-TRCP, which promote ubiquitination and degradation of the transcriptional coactivator YAP1 (REF.\textsuperscript{109}). Beneficial effects of stem cell-derived extracellular vesicles have also been shown in other CKD models, including ciclosporin, remnant kidney and DOCA salt hypertension models\textsuperscript{100–112}.

### Renal cell-derived extracellular vesicles

Renal cell-derived extracellular vesicles might have advantages for kidney regeneration compared with those from other sources owing to their renal commitment. Rat kidney tubular cell extracellular vesicles that were intravenously injected into a rat IRI model improved kidney function, reduced neutrophil infiltration and limited fibrosis\textsuperscript{91}. In addition, urinary extracellular vesicles from healthy people improved recovery of kidney morphology and function in a mouse AKI model\textsuperscript{111}. These extracellular vesicles carried the renoprotective factor klotho, which might have a central role in the observed effects.

Stem cells of renal origin are also a potential source of extracellular vesicles for therapeutic application. For example, extracellular vesicles isolated from human glomerular MSCs or from murine renal MSCs improved kidney function in mouse models of AKI\textsuperscript{115,119}. In a rat model of T1DM, extracellular vesicles isolated from urinary MSCs prevented CKD progression and limited podocyte and tubular epithelial cell apoptosis through the delivery of TGFβ1, angiogenin and bone morphogenetic protein 7 (BMP7)\textsuperscript{117}.

The application of renal cell-derived extracellular vesicles in preclinical studies and, more importantly, in future clinical practice, is limited owing to issues of poor availability, lack of sterility and immunogenicity of the cells of origin. However, detailed studies of their mechanisms of action might improve understanding of intra-nephron communication and kidney physiology. In addition, future approaches might involve engineering autologous non-renal extracellular vesicles to recapitulate the therapeutic properties of renal cell-derived extracellular vesicles.

### Graft preconditioning

Machine perfusion of donor kidneys before transplantation could improve organ preservation and reduce ischaemic injury, potentially resulting in improved graft function. In addition, this strategy might enable organ quality and viability to be improved before transplantation, potentially increasing the donor pool\textsuperscript{108}. Addition of extracellular vesicles to the perfusion solution could
be an innovative strategy for delivering pro-regenerative molecules to the graft before transplantation (FIG. 4). To date, only a few studies have investigated the feasibility and efficacy of this strategy in lung, liver and kidney transplantation\(^{19}\). The delivery of MSC extracellular vesicles to rat deceased donor kidneys during 4 h of cold perfusion protected against ischaemic injury\(^{20}\). Histological and molecular analyses of the extracellular vesicle-perfused kidneys showed upregulation of enzymes involved in energy metabolism. This result was corroborated by the presence of lactate, lactate dehydrogenase and glucose in the effluent fluid, which confirmed that the extracellular vesicle-perfused kidneys had higher energy substrate consumption than the control perfused kidneys.

Similar positive results were obtained in a single-centre, prospective, pilot, randomized clinical study that evaluated the effects of 4 h of hypothermic oxygenated machine perfusion with and without the delivery of BM-MSC extracellular vesicles on marginal kidney pairs that were considered unsuitable for transplantation\(^{21}\). The BM-MSC extracellular vesicle-treated kidneys \((n = 5)\) showed improved preservation of the renal architecture and mitochondrial morphology, less tubular damage and lower caspase 3 expression (indicating a protective effect against apoptosis) compared with the control perfused kidneys. Although these data are promising, further studies evaluating graft function over time are needed to investigate the long-time efficacy of the intervention.

**Nephroprotective cargo molecules**

The nephroprotective effects of extracellular vesicles have been attributed to the activity of numerous molecules within their cargo that reprogram the gene expression profile of recipient cells. Extracellular vesicles have anti-apoptotic, anti-inflammatory and anti-fibrotic activities. In-depth studies have dissected the roles of extracellular RNAs and, in particular, miRNAs, present within extracellular vesicles in their beneficial functions. A central role of miRNAs was supported by a study that used extracellular vesicles isolated from MSCs with knockdown for Drosha, which is a crucial nuclear enzyme involved in miRNA maturation\(^{22}\). These extracellular vesicles showed downregulation of miRNAs and, unlike wild type MSC extracellular vesicles, did not improve recovery of kidney function in a mouse model of AKI\(^{122}\). RNA sequencing analysis showed that the gene expression profiles of AKI kidneys that were treated with wild type MSC extracellular vesicles, but not those that were treated with Drosha-knockdown MSC extracellular vesicles, correlated with those of healthy kidney tissue. This finding underlines the broad effects of extracellular vesicles on injured tissues, possibly acting on multiple cells and targets through a synergy of factors. Such broad effects could be highly relevant in the context of fibrotic damage, in which overlapping pathways and mechanisms are dysregulated and therapeutic strategies that target a single factor have generally been ineffective\(^{104,105}\).

The beneficial effects of individual extracellular vesicle miRNAs, mainly those carried by MSC extracellular vesicles, have also been investigated. miR-133b-3p and miR-294 were reported to limit tubular TGFβ-induced epithelial-to-mesenchymal transition in vitro\(^{123}\). The let-7 family miRNAs might also have a role in the antifibrotic activity of extracellular vesicles\(^{24}\). Let-7c and let-7b were shown to target TGFβR1 and inhibit the TGFβ pathway, resulting in reductions in kidney fibrosis in UUO and DKD models\(^{125,126}\). Other miRNAs, such as miRNA-30a, miRNA-24 and miRNA-21, which are enriched in MSC extracellular vesicles derived from BM or liver tissue, target genes involved in fibrosis progression such as Colla1, Acta2 and Snai1\(^{104,105}\). miR-30 carried by Wharton jelly MSC extracellular vesicles was reported to inhibit mitochondrial fission in a model of IRI\(^{127}\), whereas miR-26a present in adipose MSC extracellular vesicles was shown to protect against DKD by targeting TLR4\(^{108}\). In a kidney IRI model, miR-199a-3p carried by MSC extracellular vesicles inhibited apoptosis by downregulating semaphorin 3A\(^{129}\).

Proteomic analyses of MSC extracellular vesicles have identified several growth factors, including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), insulin-like growth factor I (IGF) and hepatocyte growth factor (HGF), that are involved in multiple mechanisms of tissue regeneration and repair, including regulation of inflammation, extracellular matrix remodelling, the cell cycle, cell migration, morphogenesis and angiogenesis\(^{125,126,129}\). These data highlight the complexity and synergistic activity of the extracellular vesicle cargo.

**Fig. 4 | Application of stem cell-derived extracellular vesicles for kidney graft preconditioning.** The addition of stem cell-derived extracellular vesicles to the perfusion solution during machine perfusion of donor kidneys before transplantation might protect the kidney graft from ischaemic damage, stimulate pathways involved in energy metabolism and protect mitochondria and tubular cells from damage and apoptosis\(^{121}\).
Biodistribution of extracellular vesicles

As extracellular vesicles are rapidly cleared by the immune system and specific organs, such as liver and spleen, their biodistribution must be considered when investigating their therapeutic potential\(^{136}\). Use of live and high-resolution microscopy techniques in combination with labelling strategies using lipid or luminal dyes or genetic approaches using fluorescent or bioluminescent reporters has improved understanding of the behaviour and fate of extracellular vesicles in vivo\(^{131}\). The most commonly used lipophilic dyes, such as PKH67, DiR and DiD, can aggregate and form particles, limiting the specificity of their application. Luminal dyes such as carboxyfluorescein diacetate succinimidyl ester (CFDA-SE), depend on the presence of luminal esterases for their conversion into a fluorescent probe. Use of these dyes reduces the fluorescent background compared with that of lipophilic dyes, but the signal is limited to extracellular vesicles that express esterases\(^{132}\).

Genetically engineered reporters including green or red fluorescent proteins can be linked to specific extracellular vesicle proteins, such as tetraspanins\(^{133}\). Crisp-Cas9 technology has also been exploited to generate functional reporters for tissue localization of extracellular vesicles. A transgenic reporter mouse that used Cre-dependent extracellular vesicle labelling under the renal promoter Pax8 enabled the detection of tubular epithelial cell-derived extracellular vesicles in urine\(^{135}\). This strategy provides a new approach to studying cell-specific extracellular vesicles in vivo.

Although the kidney does not seem to be a main target for extracellular vesicles, increased vascular permeability during kidney damage may favour their intrarenal localization. Extracellular vesicles preferentially localize within injured kidneys compared with healthy kidneys\(^{93}\). In AKI models, stem cell-derived extracellular vesicles labelled with DiD or red fluorescent dye localized within peritubular capillaries and tubules as early as 1 h after intravenous injection, with a peak after 6 h and a decrease after 24 h (REFS\(^{123,124}\)). Extracellular vesicle surface molecules might have a role in their tissue retention; for example, endothelial colony-forming cell-derived extracellular vesicles have been reported to selectively target ischaemic kidneys via the exosomal CXC-chemokine receptor 4 (CXCR4)\(^{134}\). In this study, the extracellular vesicles, which were labelled with lipophilic dye and detected 30 min after kidney reperfusion, rapidly transferred miR-486-5p to endothelial cells, glomeruli and proximal tubules.

Tracking of human placenta-derived MSCs extracellular vesicles expressing Gaussia luciferase using a high-resolution intravital in situ imaging technique in a transgenic mouse AKI model, confirmed their accumulation in injured kidneys and showed that they promoted the expansion of transcription factor SOX9" cells, which are known to be involved in kidney regeneration\(^{76}\). Accumulation of MSC extracellular vesicles in injured kidneys was also demonstrated in an IRI mouse model using real-time in vivo imaging and labelling with an aggregation-induced emission luminogen that enabled high-resolution tracking of the extracellular vesicles\(^{135}\). This study reported that the extracellular vesicles were taken up by proximal tubule epithelial cells and stimulated mitochondrial antioxidant defence and ATP production, resulting in a reduction in mitochondrial fragmentation. The use of genetically engineered extracellular vesicles in combination with innovative detection technologies will enable further elucidation of the fate of extracellular vesicles in vivo following infusion and their effects at the single-cell level.

Extracellular vesicle engineering

Extracellular vesicles are an efficient, naturally targeted delivery system. They are able to protect their cargo, such as RNA species, against degradation and to evade phagocytosis more efficiently than liposomes. They also have reduced immunogenicity compared with liposomes and express surface ligands for damage-induced molecules that enable their specific uptake by damaged cells\(^{140}\). Extracellular vesicles are therefore attractive candidates for delivering renoprotective agents. Although the majority of applications of engineered extracellular vesicles as drug delivery systems investigated to date are in the oncology field, a few studies have shown efficacy of this approach in kidney disease models (TABLE 2). In a mouse AKI model, loading IL-10 into extracellular vesicles enhanced the stability of this cytokine and its targeting to the injured kidney\(^{132}\). Similarly, extracellular vesicles that were engineered to express human recombinant klotho had greater renoprotective effects than the equivalent dose of soluble klotho in a mouse model of AKI\(^{76}\).

Engineering strategies could also be used to enhance the natural therapeutic activity of extracellular vesicles. However, direct miRNA or mRNA extracellular vesicle engineering strategies using electroporation have had limited success, possibly because of the alteration of the therapeutic cargo during this manipulation. For example, in a mouse AKI model, MSC extracellular vesicles that were loaded with selected miRNAs only improved renal regeneration compared with non-engineered MSC extracellular vesicles when the administered dose was low\(^{140}\). The number of miRNAs that can be packaged in extracellular vesicles is still debated; this issue is important because the absolute number of miRNA present in extracellular vesicles may correlate with their activity\(^{139}\). Transfection protocols should be carefully optimized by modulating voltage and pulse to minimize vesicle damage and to maximize cargo loading\(^{140}\). However, loading of extracellular vesicles with RNAs by electroporation is very prone to artefacts owing to the presence of residual RNA aggregates and to extracellular vesicle disruption\(^{140}\). For these reasons, alternative strategies to load extracellular vesicles with miRNAs such as co-incubation have also been investigated. A study that used a co-incubation strategy to load human liver stem cell extracellular vesicles with antitumour miR-145 reported that the loaded vesicles were more effective at inhibiting the invasive properties of cancer stem cells than non-loaded vesicles\(^{32}\).

Even more encouraging results have been obtained using extracellular vesicles derived from engineered cells. For example, extracellular vesicles from MSCs that were engineered to express human erythropoietin
(EPO) were able to transfer EPO mRNA to target cells and alleviate anaemia in CKD mice\textsuperscript{143}. Moreover, transfecting MSCs with a let-7i-5p antagomir increased the anti-fibrotic activity of the secreted extracellular vesicles, resulting in a reduction in extracellular matrix deposition and attenuation of epithelial-to-mesenchymal transition in vitro and in vivo in a UUO model\textsuperscript{144}. In the same model, extracellular vesicles from MSCs that were engineered to express gial cell line-derived neurotrophic factor decreased peritubular capillary rarefaction and tubulointerstitial fibrosis by targeting the SIRT1 signaling pathway\textsuperscript{145}. Compared with normal MSC extracellular vesicles, those that were generated from MSCs that overexpressed the transcription factor octamer-binding protein 4 (OCT4) had a greater inhibitory effect on Snai1 expression and increased anti-apoptotic and proliferative effects on renal cells in a mouse kidney IRI model\textsuperscript{146}.

Preconditioning of extracellular vesicle-releasing cells might also influence their content and potentially increase their regenerative properties. For example, hypoxia preconditioning of MSCs increased the angiogenic potential of the released extracellular vesicles\textsuperscript{147}. By contrast, MSCs that were cultured with pro-inflammatory cytokines released extracellular vesicles that were enriched in metalloprotease inhibitor 1 (TIMP1), CD39 and CD73 and had greater anti-angiogenic effects than extracellular vesicles from MSCs that were cultured under normal conditions\textsuperscript{148}.

An alternative strategy to increase the therapeutic efficacy of extracellular vesicles while preserving their integrity is modulation of their stability and biodistribution. The route of administration is an important factor that influences extracellular vesicle accumulation at the site of interest. The majority of preclinical studies have used sub-renal capsule or direct intrarenal parenchyma administration\textsuperscript{138,139}. Local delivery approaches may enable the use of lower doses of extracellular vesicles but are more invasive than intravenous injection. Hydrogels containing RGD (Arg-Gly-Asp) peptides have been shown to enhance the binding of extracellular vesicles to injured kidney cells that expressed RGD binding integrins on their surface\textsuperscript{149}. In a mouse AKI model, extracellular vesicles that were entrapped within hydrogels and injected under the renal capsule were more effective than free extracellular vesicles at limiting tubular injury in the early stages of AKI and limiting fibrosis in the later stages\textsuperscript{138}. Similar benefits were obtained by encapsulating extracellular vesicles within a collagen matrix and injecting them intrarenally into three different sites to favour their controlled release\textsuperscript{140}.

Pulsed focused ultrasound, consisting of a high-intensity pulse of sound waves, can be externally applied to control and modulate the local cargo release of

### Table 2 | Effects of engineered extracellular vesicles in kidney disease models

| Extracellular vesicle origin | Engineering approach | Model | Type of injury | Effects | Ref. |
|-----------------------------|---------------------|-------|---------------|---------|-----|
| Urine                       | Klotho expression   | Rhabdomyolysis | AKI         | Increased endogenous klotho levels and reduced αSMA and CTGF levels in kidney cells | 134 |
| RAW 264.7 macrophages       | Loading with IL-10  | IRI   | AKI          | Suppressed mammalian target of rapamycin signalling and promoted mitophagy and M2 macrophage polarization, which can suppress inflammation | 137 |
| Bone marrow MSCs            | Transfection with specific miRNA mimics (miR-10a, miR-127 and miR-486) | Rhabdomyolysis | AKI         | Reduced tubular cell injury at a lower therapeutic dose than naive extracellular vesicles | 138 |
|                             | Transfection with let-7i-5p antagomir | UUO   | CKD          | Reduced let-7i-5p level in kidney tubular epithelial cells, ECM deposition and EMT and increased activation of TSC1–mTOR signalling | 139 |
| Kidney MSCs                 | Lentiviral transfection of human EPO mRNA | Renal anaemia | CKD         | Induced EPO expression in kidney cells, increased haemoglobin levels and decreased serum creatinine and BUN | 140 |
| Adipose MSCs                | Lentiviral transfection of GDNF mRNA | UUO   | CKD          | Activated the SIRT1–eNOS signalling pathway in proximal tubular cells and reduced fibrosis | 141 |
| Umbilical cord MSCs         | Lentiviral transfection of OCT4 mRNA | IRI   | AKI          | Reduced apoptosis and increased proliferation of renal tubular epithelial cells | 142 |
| Human placental MSCs        | Encapsulation of extracellular vesicles within a hydrogel containing Arg-Gly-Asp peptides | IRI   | AKI and CKD  | Increased efficacy of encapsulated extracellular vesicles compared with free extracellular vesicles | 143 |
|                             | Encapsulation of extracellular vesicles within a collagen matrix | IRI   | AKI          | Increased efficacy of encapsulated extracellular vesicles compared with free extracellular vesicles | 144 |
| Red blood cells             | Surface expression of KIM1-binding peptide and cargo expression of P65 and Snai1 siRNAs | IRI and UUO | AKI and CKD | Reduced P-p65 and Snai1 expression, renal inflammation and fibrosis | 145 |

αSMA, α-smooth muscle actin; AKI, acute kidney injury; CKD, chronic kidney disease; CTGF, connective tissue growth factor; ECM, extracellular matrix; EMT, epithelial-to-mesenchymal transition; eNOS, endothelial nitric oxide synthase; EPO, erythropoietin; IRI, ischaemia–reperfusion injury; KIM1, kidney injury molecule 1; mRNA, microRNA; MSC, mesenchymal stromal cell; mTOR, mammalian target of rapamycin; SIRT1, sirtuin 1; SNAI1, zinc-finger protein SNAI1; TSC1, tuberous sclerosis complex subunit 1; UUO, unilateral ureteral obstruction.
circulating extracellular vesicle. This ultrasound technique increased the efficacy of MSC extracellular vesicles without altering their homing to the kidney in a mouse model of cisplatin-induced AKI.151

Finally, engineering of biologically inactive extra-
cellular vesicles from easily available and potentially autologous sources could be a very promising approach for targeted delivery of therapeutics. For example, blood cell-derived extracellular vesicles that were engineered to express a kIM-1-targeting peptide and loaded with short interfering RNAs for the transcription factors p65 and snail1, efficiently delivered these short interfering RNAs to injured kidney tubules and thereby reduced tubulointerstitial inflammation and fibrosis in mouse models of AKI.152

Clinical application

A number of clinical trials are testing the safety and efficacy of extracellular vesicles from various stem cell sources for organ repair. The first in-human study reported the compassionate use of MSC extracellular vesicles in a patient with steroid-resistant graft versus host disease and showed the safety of this approach.153

Administration of the extracellular vesicles quickly improved the patient’s symptoms, including diarrhoea and cutaneous and mucosal graft versus host disease.152

To date, only one trial has tested the efficacy of MSC extracellular vesicles in kidney disease. This single-centre, randomized, placebo-controlled, phase II/III clinical trial enrolled 40 patients with CKD stage III or IV.154 Two doses of umbilical cord MSC extracellular vesicles were administered 1 week apart (the first dose was injected intravenously and the second dose was injected into the intrarenal arteries) and patients were followed for 12 months. The treated patients showed a significant improvement in kidney function compared with those in the placebo group, as evaluated by glomerular filtration rate, albuminuria and plasma levels of creatinine and urea. In addition, kidney biopsy samples taken from responding patients 3 months after treatment showed increases in the numbers of proliferating Ki67 cells and renal progenitor CD133+ cells, providing evidence of kidney regeneration. The treatment also induced downregulation of anti-inflammatory TNFα and upregulation of anti-inflammatory TGFβ1 and IL-10 in patient plasma. These data support the safety and efficacy of MSC extracellular vesicle administration in patients with CKD. Unfortunately, the researchers do not provide information on the development of anti-HLA antibodies in recipients of the MSC extracellular vesicles, which is of clinical relevance for patients with CKD who might require future kidney transplantation, as the presence of these antibodies can lead to hyperacute rejection and graft loss.

Since the beginning of the COVID-19 pandemic, a number of clinical trials have investigated the efficacy of MSC extracellular vesicles in patients with COVID-19 (REF.155). These trials have highlighted the feasibility of extracellular vesicle production and administration in a clinical setting, supporting their use as a novel therapeutic tool. For example, a prospective, non-randomized open-label cohort study in 24 patients with severe COVID-19 and moderate-to-severe acute respiratory distress syndrome reported that intravenous infusion of allogeneic BM-MSC extracellular vesicles was safe, improved hypoxia and immune reconstitution and downregulated the cytokine storm.156 However, accurate and extensive characterization of the injected extracellular vesicle base product is necessary to guarantee reproducible, scalable, and well-controlled studies.157

The clinical application of MSC extracellular vesicles is limited by the lack of clear criteria for standardization of extracellular vesicle preparation.158 Consensus has been achieved on the definition of therapeutically active MSC extracellular vesicles, which is restricted to small extracellular vesicles (<200 nm in size) expressing mesenchymal and extracellular vesicle markers coupled with a tested functional activity of relevance for the desired therapeutic use.159,160 The generation of master and/or working cell banks to provide a stable pool of producer cells for extracellular vesicles is fundamental for their clinical translation. Techniques required for large-scale extracellular vesicle isolation, such as tangential flow filtration to enable their extraction from large volumes, are under development. Extracellular vesicle integrity and purity from contaminants, such as growth factors and miRNAs present in cell-culture media, as well as endotoxins, are critical factors that must be considered.161 In addition, scalable, reproducible and good manufacturing practice-compliant protocols for the manufacture of extracellular vesicle products must be developed. Nevertheless, various products are under development, including cell secretome products, native extracellular vesicles and engineered extracellular vesicles, with the aim of treating a large range of conditions such as cancer and orthopaedic, neurological, ophthalmological and cardiovascular diseases.162

Conclusions

Extracellular vesicles have roles in in cell-to-cell and organ-to-organ crosstalk that may amplify kidney damage and contribute to the progression of kidney disease. Moreover, the complex cargo of extracellular vesicles reflects the type and pathophysiological status of the originating cells. The functions of extracellular vesicles and their applications as biomarkers and therapeutic agents constitute an expanding field of great interest for clinical translation. Researchers are now leveraging advances in nanotechnologies that enable evaluation of single extracellular vesicles, such as super resolution microscopy, nanoflow cytometry and single extracellular vesicle capture arrays, in mechanistic and biomarker studies.163 Ideally, the development of approaches for single-vesicle analysis will enable correlation of the type of extracellular vesicle-releasing cell with its cargo, representing a new type of liquid biopsy.

The application of urinary extracellular vesicles as biomarkers is limited by the heterogeneity of the urine and rigorous protocols for extracellular vesicle analysis and normalization are required.159 Whether organ-derived and/or serum extracellular vesicles can be identified within the urine and exploited as biomarkers is currently unclear. Although preclinical data suggest that extracellular vesicles could have beneficial effects in AKI...
and CKD, human studies are limited and clinical trials are needed to validate these findings. New frontiers in this field include the use of natural or autologous sources of extracellular vesicles and extracellular vesicle engineering. Increased knowledge of extracellular vesicles could also inspire the engineering of biomimetic synthetic particles, for example, by loading synthetic cargo within extracellular vesicle membrane-coated particles or by building artificial extracellular vesicle mimics.

To enable clinical translation of extracellular vesicle products, tests of their identity (that is, precise characterization relative to their mechanism of action) and their potency (that is, their effects in relation to the desired therapeutic use) need to be defined. To date, no extracellular vesicle product has been approved by regulatory agencies. The extracellular vesicle community is committed to the development of standardized protocols for the scalable production, characterization and storage of extracellular vesicles, as well as preclinical and clinical approaches to assessing their safety and efficacy.

Published online 31 May 2022
56. Barutta, F. et al. Urinary exosomal microRNAs in incontinent diabetic nephropathy. PLoS ONE 8, e75798 (2013).
57. Lu, L. L. et al. MicroRNA-23c in urinary exosome/ microvesicle and its potential as a marker of alport syndrome. Am. J. Physiol. Renal Physiol. 305, F1220–F1227 (2013).
58. Khurana, R. et al. Identification of urinary exosomal noncoding RNAs and their potential as a biomarker in chronic kidney disease. RNA 25, 142–152 (2017).
59. Kumari, M. et al. miR-451 loaded exosomes are released by the injured cells in response to injury and associated with reduced kidney function in human. Front. Physiol. 11, 254 (2020).
60. Min, Q.-H. et al. Differential expression of urinary exosomal miR-491 and exosomal RNA. J. Clin. Lab. Anal. 32, e22226 (2018).
61. Solé, C., Molinet, T., Vidal, M., Ord-Ros, J. & Courad, C. Circulating urinary miRNA signature for early diagnosis of renal fibrosis in lupus nephritis. Cells 8, 773 (2019).
62. Ha, H. et al. Differential expression study of circular RNAs in exosomes from serum and urine in patients with idiopathic membranoproliferative nephropathy. Arch. Med. Coll. 15, 758–753 (2019).
63. Grange, C. et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 71, 5336–5346 (2011).
64. De Palma, G. et al. The three-gene signature in urinary extracellular vesicles from patients with clear cell renal cancer. Am. J. Clin. Pathol. 140, 1960–1967 (2016).
65. Raimondo, F. et al. Differential protein profiling of renal cell carcinoma urinary exosomes. Mol. Biol. Syst. 11, 288 (2015).
66. US National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04053855
67. Butz, H. et al. Exosomal MicroRNA are diagnostic biomarkers and can mediate cell-cell communication in renal cell carcinoma. Eur. Urol. Focus 2, 210–218 (2016).
68. Kurahashi, R. MicroRNA-204-5p: a novel candidate tumor antigen for renal tumors. Int. J. Oncol. 53, 87–90 (2018).
69. Fujii, N. et al. Extracellular miR-224 as a prognostic marker in clear cell renal cell carcinoma. Oncotarget 7, 109877–109888 (2017).
70. Wang, X. et al. Serum exosomal miR-210 as a novel urinary biomarker of Xp11.2 translocation renal cell carcinoma. Exp. Mol. Med. 51, e44092 (2019).
71. Park, J. T. et al. Repression of let-7 by transforming growth factor receptor 73 by sunitinib resistance in renal cancer by acting as microRNA-dependent repairing. Stem Cell Res. Ther. 9, 12203–12213 (2020).
72. Grange, C. et al. Urinary extracellular vesicles carrying klotho improve survival in an acute tubular injury model. Mol. Sci. Rep. 28, 490–502 (2020).
73. Ranaghi, A. et al. The effects of glomerular and tubular proximal and distal extracellular vesicles on recovery from acute kidney injury. Stem Cell Res. Ther. 8, 24 (2017).
74. Choi, H. Y. et al. Microvesicle secreted from kidney-derived mesenchymal stem cells act as carriers of proangiogenic signals and contribute to recovery from acute kidney injury. Stem Cells Transl. Med. 9, 1220–1233 (2020).
75. Gregorini, M. et al. Perfusion of isolated rat kidney extracellular vesicles prevent aristolochic acid-induced renal oxidative stress and apoptosis in vivo. Kidney Int. 90, 1239–1250 (2016).
76. Duan, Y. et al. Adipose mesenchymal stem cell-derived extracellular vesicles containing microRNA-26a-5p target TLRA and protect against sunitinib-induced renal fibrosis. J. Biol. Chem. 290, e44079–e44089 (2015).
77. Wang, Y. et al. Bone marrow-derived mesenchymal stem cell-secreted extracellular vesicles inhibit and revert fibrosis progression in a mouse model of diabetic nephropathy. Sci. Rep. 9, 4468 (2019).
78. Bubnov, A. et al. Human embryonic mesenchymal stem cell-derived conditioned medium rescues kidney function in rats with established chronic kidney disease. PLoS ONE 7, e88746 (2012).
79. Lindosso, R. S. et al. Adipose mesenchymal cell-derived EVs achieve DOCA-salt-hypertension induced by promoting cardio-renal protection. Mol. Ther. Metab. Dis. 6, 89–99 (2016).
80. Domínguez, J. H. et al. Renal tubular cell-derived extracellular vesicles accelerate the recovery of established renal fibrosis by promoting cardiorenal protection. J. Am. Soc. Nephrol. 28, 3553–3554 (2017).
81. Grange, C. et al. Urinary extracellular vesicles carrying klotho improve survival in an acute tubular injury model. Mol. Sci. Rep. 28, 490–502 (2020).
82. Reis, L. A. et al. Bone marrow-derived mesenchymal stem cells repaired but did not prevent gentamicin-induced acute kidney injury through paracrine effects in rats. PLoS ONE 7, e4492 (2012).
83. Shi, Z., Wang, Q., Zhang, Y. & Jiang, D. Extracellular vesicles produced by bone marrow mesenchymal stem cells attenuate renal injury by inhibiting RhoA/ROCK pathway in a ULO rat model. Stem Cells Res. Ther. 11, 253 (2020).
84. Kohtala, S. et al. Urinary extracellular vesicles ameliorate kidney injury in aristolochic acid nephropathy. Front. Cell Dev. Biol. 8, 88 (2020).
85. Kohtala, S. et al. Human liver stem cell-derived extracellular vesicles prevent aristolochic acid-induced kidney fibrosis. Front. Immunol. 9, 1635 (2018).
86. Grange, C. et al. Stem cell-derived extracellular vesicles inhibit and revert fibrosis progression in a mouse model of diabetic nephropathy. Sci. Rep. 9, 4468 (2019).
87. Bubnov, A. et al. Human embryonic mesenchymal stem cell-secreted extracellular vesicles inhibit and revert fibrosis progression in a mouse model of diabetic nephropathy. Sci. Rep. 9, 4468 (2019).
88. Browning, B. et al. Transforming growth factor-β1-mediated regulation of extracellular vesicles. J. Clin. Invest. 125, 352–361 (2014).
127. Gu, D. et al. Mesenchymal stromal cells derived extracellular vesicles ameliorate acute renal ischemia reperfusion injury by inhibition of mitochondrial fission through miR-30. Stem Cells Int. 2016, 2095940 (2016).

128. Zhu, G. et al. Exosomes from human-bone-marrow-derived mesenchymal stem cells protect against renal ischemia/reperfusion injury via transferring miR-199a-5p. J. Cell. Physiol. 234, 25736–25749 (2019).

129. Anderson, J. D. et al. Comprehensive proteomic analysis of mesenchymal stem cell exosomes reveals modulation of angiogenesis via nuclear factor-kappab signaling. Stem Cell 34, 601–613 (2016).

130. Takahashi, Y. et al. Visualization and in vivo tracking of mesenchymal stem cell-derived extracellular vesicles: a new therapeutic platform for RNAi to treat AKI. J. Am. Soc. Nephrol. 24, 3601–3615 (2013).

131. Ge, L. et al. Extracellular vesicles derived from hypoxia-preconditioned olfactory mucosa mesenchymal stem cells enhance angiogenesis via miR-612. J. Nanobiotechnol. 19, 380 (2021).

132. Angioni, R. et al. CD73+ extracellular vesicles inhibit angiogenesis through adenosine A2a receptor signalling. J. Extracell. Vesicles 9, 1757900 (2020).

133. Borrero, V. et al. International Society for Extracellular Vesicles: guidelines and recommendations. Eur. J. Clin. Pharmacol. 78, 12133–12147 (2020).

134. Kordelas, L. et al. MSC-derived small extracellular vesicles for therapeutic applications of mesenchymal stromal cell-derived small extracellular vesicles. Cytotherapy 25, 375–380 (2021).

135. Witwer, K. W. et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. J. Extracell. Vesicles 8, 1609206 (2019).

136. Nordin, J. Z., Bostancioglu, R. B., Corso, G. & El Andaloussi, S. Tangential flow filtration with or without subsequent bind-elute size exclusion chromatography for purification of extracellular vesicles. Methods Mol. Biol. 1953, 287–299 (2019).

137. Arab, T. et al. Characterization of extracellular vesicles and synthetic nanoparticles with four orthogonal single-particle analysis platforms. J. Extracell. Vesicles 10, e12079 (2021).

138. Choi, H. et al. Kidney mesenchymal stem cell-derived extracellular vesicles engineered to express erythropoietin improve renal anemia in mice with chronic kidney disease. Stem Cell Rev. Rep. 18, 980–992 (2022).

139. Jin, J. et al. Mesenchymal stem cell attenuates renal fibrosis via exosomes-mediated delivery of microrna Let-7i-5p antagonist. Int. J. Nanomed. 16, 3565–3578 (2021).

140. Chen, L. et al. Exosomes derived from GDNF-modified human adipose mesenchymal stem cells ameliorate peri-infarct capillary loss in tubulointerstitial fibrosis by activating the SIRT1/eNOS signalling pathway. Theranostics 10, 9425–9442 (2020).

141. Zhang, Z. Y. et al. Oct-4 enhanced the therapeutic effects of mesenchymal stem cell-derived extracellular vesicles in acute kidney injury. Kidney Blood Press. Res. 45, 95–108 (2020).

142. Hielscher, T. A. et al. Extracellular vesicles: a new therapeutic strategy to improve the anti-tumor effect of stem cell-derived EVs. Pharmaceutics 13, 76 (2021).

143. Cho, H. Y. et al. Kidney mesenchymal stem cell-derived extracellular vesicles engineered to express erythropoietin improve renal anemia in mice with chronic kidney disease. Stem Cell Rev. Rep. 18, 980–992 (2022).

144. Zöller, M. et al. Isolation of cell-specific extracellular vesicles. Int. J. Mol. Sci. 20, 9553 (2020).

145. Nørgård, M. O. et al. A new transgene mouse model using an extravesicular EGFP tag enables affinity isolation of cell-specific extracellular vesicles. Sci. Rep. 12, 496 (2022).

146. Brossa, A. et al. Concubination as miR-loading strategy to improve the anti-tumor effect of stem cell-derived extracellular vesicles: a new therapeutic platform for RNAi to treat AKI. J. Extracell. Vesicles 9, 1757900 (2020).

147. Wang, G. et al. Oct-4 enhanced the therapeutic effects of mesenchymal stem cell-derived extracellular vesicles in acute kidney injury. Kidney Blood Press. Res. 45, 95–108 (2020).

148. Zeng, Y. et al. Oct-4 enhanced the therapeutic effects of mesenchymal stem cell-derived extracellular vesicles in acute kidney injury. Kidney Blood Press. Res. 45, 95–108 (2020).

149. Kordelas, L. et al. Mesenchymal stem cell-derived extracellular vesicles for therapeutic applications. J. Extracell. Vesicles 8, 1609206 (2019).

150. Nordin, J. Z., Bostancioglu, R. B., Corso, G. & El Andaloussi, S. Tangential flow filtration with or without subsequent bind-elute size exclusion chromatography for purification of extracellular vesicles. Methods Mol. Biol. 1953, 287–299 (2019).

151. Arab, T. et al. Characterization of extracellular vesicles and synthetic nanoparticles with four orthogonal single-particle analysis platforms. J. Extracell. Vesicles 10, e12079 (2021).

152. Ge, L. et al. Extracellular vesicles derived from hypoxia-preconditioned olfactory mucosa mesenchymal stem cells enhance angiogenesis via miR-612. J. Nanobiotechnol. 19, 380 (2021).

153. Angioni, R. et al. CD73+ extracellular vesicles inhibit angiogenesis through adenosine A2a receptor signalling. J. Extracell. Vesicles 9, 1757900 (2020).

154. Ge, L. et al. Extracellular vesicles derived from hypoxia-preconditioned olfactory mucosa mesenchymal stem cells enhance angiogenesis via miR-612. J. Nanobiotechnol. 19, 380 (2021).

155. Nordin, J. Z., Bostancioglu, R. B., Corso, G. & El Andaloussi, S. Tangential flow filtration with or without subsequent bind-elute size exclusion chromatography for purification of extracellular vesicles. Methods Mol. Biol. 1953, 287–299 (2019).

156. Sengupta, V. et al. Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cell Dev. 29, 747–754 (2020).

157. Sechi, L. et al. Exosomes from human-bone-marrow-derived mesenchymal stem cells protect against renal ischemia/reperfusion injury via transferring miR-199a-5p. J. Cell. Physiol. 234, 25736–25749 (2019).

158. Brossa, A. et al. Concubination as miR-loading strategy to improve the anti-tumor effect of stem cell-derived extracellular vesicles: a new therapeutic platform for RNAi to treat AKI. J. Extracell. Vesicles 9, 1757900 (2020).

159. Chen, L. et al. Exosomes derived from GDNF-modified human adipose mesenchymal stem cells ameliorate peri-infarct capillary loss in tubulointerstitial fibrosis by activating the SIRT1/eNOS signalling pathway. Theranostics 10, 9425–9442 (2020).

160. Zhang, Z. Y. et al. Oct-4 enhanced the therapeutic effects of mesenchymal stem cell-derived extracellular vesicles in acute kidney injury. Kidney Blood Press. Res. 45, 95–108 (2020).

161. Witwer, K. W. et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. J. Extracell. Vesicles 8, 1609206 (2019).

162. Nordin, J. Z., Bostancioglu, R. B., Corso, G. & El Andaloussi, S. Tangential flow filtration with or without subsequent bind-elute size exclusion chromatography for purification of extracellular vesicles. Methods Mol. Biol. 1953, 287–299 (2019).